Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients

Bone Marrow Transplantation

Volumn 40, Issue 2, 2007, Pages 105-110

  Iravani, M ^a   Evazi, M R ^a   Mousavi, S A ^a   Shamshiri, A R ^a   Tavakoli, M ^a   Ashouri, A ^a   Samiee, S ^a   Chahardovali, B ^a   Alimoghaddam, K ^a   Ghaffari, S H ^a   Ghavamzadeh, A ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOSPORIN A; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CONSERVATIVE TREATMENT; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT VERSUS HOST REACTION; HEMORRHAGIC CYSTITIS; HUMAN; INCIDENCE; LEUKEMIA; LEUKOCYTE COUNT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRIORITY JOURNAL; SCHOOL CHILD; SURVIVAL RATE; TACHYCARDIA; TREATMENT RESPONSE;

ADOLESCENT; ADULT; BUSULFAN; CHILD; DISEASE-FREE SURVIVAL; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 34447310874     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705685     Document Type: Article

References (27)

1. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347-1353.
2. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
3. Andersson BS, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study. Biol Blood Marrow Transplant 2002; 8: 145-154.
4. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
5. McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101: 2043-2048.
6. Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783.
7. Vaughan WP, Dennison JD, Reed EC, Klassen L, McGuire TR, Sanger WG et al. Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy. Bone Marrow Transplant 1991; 8: 489-495.
8. Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W et al. Intravenous versus oral busulfan as part of a busulfan/ cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 2002; 8: 493-500.
9. Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: Defining a therapeutic window for I.V. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002; 8: 477-485.
10. Terenzi A, Aristei C, Aversa F, Perruccio K, Chionne F, Raymondi C et al. Efficacy of fludarabine as an immunosuppressor for bone marrow transplantation conditioning: Preliminary results, Transplant Proc 1996; 28: 3101.
11. Chun HG, Leyland-Jones B, Cheson BD. Fludarabine phosphate: A synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol 1991; 9: 175-188.
12. Keating MJ, O'Brien S, Lemer S, Koller C, Beran M, Robertson LE et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92: 1165-1171.
13. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 2002; 41: 93-103.
14. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
15. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic, progenitor cell transplantation. Blood 2001; 97: 631-637.
16. Li L, Liu X, Glassman AB, Keating MJ, Stros M, Plunkett W et al. Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Cancer Res 1997; 57: 1487-1494.
17. Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hernatopoietic stem cells. Blood 2003; 102: 820-826.
18. Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468-476.
19. Chaudhry MA, Duggan P, Brown CB, Stewart D, Ruether FD, Glück S et al. Myeloablative chemotherapy for allogeneic transplantation with a fludarabine/busulfan protocol (Flubup): Comparison with Bucy. Biol Blood Marrow Transplant 2000; 6: 140.
20. Russell JA, Chaudhry AM, Duggan P, Stewart D, Ruether D, Morris D et al. Daily intravenous busulfan (BU): Comparison with conventional oral BU in combination with fludarabine as conditioning for allogeneic stem cell transplant. Blood 2000; 96: 5188.
21. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R et al. Once-daily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myelo-ablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857-864.
22. Pavletic ZS, Bishop MR, Tarantolo SR, Martin-Algarra S, Bierman PJ, Vose JM et al. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. J Clin Oncol 1997; 15: 1608-1616.
23. Bensinger WI, Clift R, Martin P, Appelbaum FR, Demirer T, Gooley T et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation. Blood 1996; 88: 2794-2800.
24. Storb R, Deeg HJ, Pepe M, Appelbaum F, Anasetti C, Beatty P et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. Blood 1989; 73: 1729-1734.
25. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
26. Common Toxicity Criteria Version 2.0. CTEP Cancer Therapy Evaluation Program [online]. 1999 April 30 [Cited 2006 April 12]; available from: http://ctep.cancer.gov.
27. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.